Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00790 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Maria Vittoria Chiaruttini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Methodology for Clinical Research, Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Despite the significant improvement in outcomes for patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs), resistance, whether primary or secondary, remains a substantial challenge. Currently, reliable biomarkers to monitor ICI response are lacking, highlighting the need for minimally invasive tools like liquid biopsy to track treatment efficacy. This study aimed to identify circulating microRNAs (miRNAs) as potential biomarkers to track ICI response in patients with NSCLC. MATERIALS AND METHODS The Apollo longitudinal study enrolled patients with advanced NSCLC receiving ICI in first or subsequent lines. Plasma samples were collected at baseline and follow-up to prospectively assess miRNA profiles until progressive disease (PD). Using a custom reverse transcription-quantitative polymerase chain reaction platform, 276 ratios among 24 lung cancer–related miRNAs were analyzed. The generalized estimating equation and joint models were applied to select the miRNA ratios most associated with PD over time. To control for multiple testing, the Benjamini-Yekutieli method was applied setting a 10% false discovery rate threshold. RESULTS From the 211 patients, a total of 454 plasma samples were analyzed. Clinical and biochemical variables had little effect on miRNAs' profile. The analysis identified nine miRNA ratios, all involving miR-145-5p, as significant biomarkers for monitoring treatment response, even after adjustment for the line of therapy. These ratios exhibited a longitudinal modulation pattern consistent with radiologic response, particularly in patients who initially benefited from ICI treatment. In addition, in an independent set of 32 plasma samples from 10 patients receiving ICI as maintenance therapy, the same trends were observed. CONCLUSION A focused panel of miRNA ratios, driven by miR-145-5p, effectively reflects response to ICI therapy in patients with advanced NSCLC, highlighting their potential as biomarkers for treatment monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Methodology for Clinical Research, Clinical Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
- Unit of Biostatistics, Epidemiology and Public Health, University of Padua, Padua, Italy.
- Thoracic Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Electronics, Information, and Bioengineering, Polytechnic University of Milan, Milan, Italy.
- Epigenomics and Biomarkers of Solid Tumors Unit, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: Maria Vittoria Chiaruttini, Miriam Segale, Anna Zanghì, Marta Brambilla, Mario Occhipinti, Marina C Garassino, Mattia Boeri
Zitieren
APA
Chiaruttini, M. V., Proto, C., Lo Russo, G., Prelaj, A., Segale, M., Zanghì, A., Galli, F., Greco, F. G., Signorelli, D., Brambilla, M., Occhipinti, M., De Braud, F., Garassino, M. C., Sozzi, G., Rulli, E., & Boeri, M. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00790
Vancouver
Chiaruttini MV, Proto C, Lo Russo G, Prelaj A, Segale M, Zanghì A, et al. Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-24-00790
BibTeX
@article{Chiaruttini2025,
author = {Chiaruttini, Maria Vittoria and Proto, Claudia and Lo Russo, Giuseppe and Prelaj, Arsela and Segale, Miriam and Zanghì, Anna and Galli, Francesca and Greco, Francesca G and Signorelli, Diego and Brambilla, Marta and Occhipinti, Mario and De Braud, Filippo and Garassino, Marina C and Sozzi, Gabriella and Rulli, Eliana and Boeri, Mattia},
title = {Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00790}
}
EUVIMED